Pioneering treatments for end-stage liver diseases through partnerships and strategic collaborations.

Promethera®  is continuously looking for new opportunities to strengthen its position as a global leader in regenerative medicine and cell therapy for liver diseases.

Promethera as a partner

Promethera® is dedicated to pioneering novel medicines with its unique setup of liver-derived allogeneic cell therapies and antibodies .

While the company is currently focused on pursuing its internal development plan with HepaStem® for the treatment of ACLF and other advanced stage liver diseases , Promethera® is always interested in additional collaborations with industry partners and academic institutions that have complimentary interests.

Promethera®’s headquarters are ideally placed in the Walloon region of Belgium. Wallonia is established as a global center of academic, clinical and manufacturing excellence for cell therapy, thanks to financial contributions from three regional sources:

Furthermore, Belgium’s location in the heart of Europe facilitates exceptional transport links across the world, providing an ideal infrastructure for the distribution of goods from our manufacturing sites to treatment centers.

Promethera® is looking to use its outstanding capabilities and expertise in liver biology and cell-based medicine, along with its strong scientific, preclinical and early-stage clinical development expertise, to build strategic collaborations .

The company would continue to act as the center of excellence for any licensed and/or jointly developed therapeutic products. Are currently developed:

Gene-Transfer Cells Augmented Therapeutic Cell Lines

Promethera® has established a combination cell-based gene therapy platform that can give rise to promising product candidates. These approaches use the clinically validated HepaStem® product.

HepaStem® consists of liver-derived mesenchymal stem cells (MSC progenitor cells) isolated from normal adult human liver tissue. The safety of these has been demonstrated in a Phase 1/2 clinical trial in 24 patients, including reinfusion of the cells. These cells could be offered as a platform for certain gene targets to express human proteins to replace defective endogenous proteins.

Finally, L’Agence Wallonne à l’Exportation et aux Investissements Étrangers (AWEX) – Belgium supports the international development of Promethera®.

For more information,
please contact our Business Development team .

Current partnerships

Promethera® has built up a series of R&D and collaborative partnerships with both industrial and academic partners, allowing Promethera® to broaden and accelerate its clinical development .

Academic partnerships

UCLouvain and the Pediatric Hepatology and Cell Therapy Laboratory

Promethera® has an ongoing collaboration agreement with UCLouvain and the Pediatric Hepatology and Cell Therapy Laboratory.

Collaborative projects

Promethera® has received a strong support and additional funding from the following organizations:

The Walloon Region, Belgium (DGO6) and the EU have granted a total sum of €22.1 million in conditional loans and subsidies for Promethera® to develop its cell therapy products and conduct clinical studies for targeted indications

  • €19.5 million in RCAs
  • €2.5 million in subsidies
  • €1.8 million from FEDER funds (European Fund for Economic and Regional Development)

Le Fonds Européen de Développement Régional et la Wallonie investissent dans votre avenir

In addition, Promethera® has also received a 12,09% (1.160.640€) regional grant from the Walloon Region and another 8,06% (773.760€) grant financed by FEDER and the EU . These grants will be used to finance the design and construction of the new Promethera® facilities located in the Walloon Cell Therapy Platform (PWTC) in Gosselies, Belgium. This new location will allow for large-scale distribution and logistics of Promethera® therapeutical products.

Finally, L’Agence Wallonne à l’Exportation et aux Investissements Étrangers (AWEX) – Belgium supports the international development of Promethera®.